Skip to content

Clinical Value of Prick Therapy Combined With Wheat Grain Moxibustion in the Treatment of Spleen Deficiency and Dampness Obstructed Cancer

Exploring the Therapeutic Effect of Pricking Therapy Combined With Wheat Grain Moxibustion on Malignant Tumors of Spleen Deficiency and Dampness Resistance Type

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06074718
Enrollment
100
Registered
2023-10-10
Start date
2024-01-02
Completion date
2024-09-30
Last updated
2024-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pricking Therapy on the Back Shu Points, Wheat Grain Moxibustion on the Back Shu Points

Keywords

spleen deficiency and dampness obstructed, cancer

Brief summary

This study aims to investigate the clinical efficacy and associated immune and inflammatory mechanisms in patients with malignant tumors of spleen deficiency and dampness resistance type, by applying pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points.

Interventions

OTHERpricking therapy and wheat grain moxibustion

pricking therapy and wheat grain moxibustion on the back shu points or positive reaction points

Sponsors

Jiangsu Taizhou People's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Western medicine and traditional Chinese medicine for malignant tumors; * Clinical diagnosis of spleen deficiency dampness obstruction in traditional Chinese medicine; * Good compliance and signed informed consent form.

Exclusion criteria

* Patients who cannot lie prone for a long time; * Pregnant women; * Lactating women

Design outcomes

Primary

MeasureTime frameDescription
Progression-Free Survival (ORR)3 yearsEvaluate the objective response rate (ORR) of subjects based on RECIST V1.1

Secondary

MeasureTime frameDescription
progression free survival (PFS),5 yearsEvaluate subjects' progression free survival (PFS), overall survival (OS), and duration of remission (DOR) based on RECIST V1.1
overall survival (OS)5 yearsEvaluate subjects' overall survival (OS) based on RECIST V1.1
duration of remission (DOR)5 yearsEvaluate subjects' duration of remission (DOR) based on RECIST V1.1

Countries

China

Contacts

Primary ContactQingtao Ni
nqt1990@126.com18852656280

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026